Advagraf is expected to improve long-term compliance with its more convenient once-daily dosing option for patients.

Mr. Teruo Yasufuku, Managing Director, Astellas Pharma India said, "Most organ transplant recipients are on multiple drug regimens, which makes life-long adherence a major challenge. With the launch of our proprietary immunosuppressant drug, we will be able to significantly address adherence issues associated with once-daily dosing compared with twice-daily dosing regimens."

Mr. Himanshu Dave, Director-Sales & Marketing, Astellas Pharma India, added "In a world where compliance can change the outcome due to the multiple dosages that were required every day, Advagraf will simplify dosing and address the issue on non adherence to treatment for preventing rejection in patients, who have undergone kidney and liver transplant surgery."